FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/12/099004 [Registered on: 12/12/2025] Trial Registered Prospectively
Last Modified On: 13/12/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Preventive 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Comparing Two Heparin Treatments to Reduce IV-Related Vein Inflammation in Children. 
Scientific Title of Study   A Prospective Randomized Study on the Efficacy of Heparin QPS Solution and Heparin Gel in Preventing Superficial Thrombophlebitis in Children 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Deebika M 
Designation  Junior resident Pediatrics 
Affiliation  chettinad hospital and research institute 
Address  chettinad hospital
OMR kelambakkam
Chennai
TAMIL NADU
603103
India 
Phone  09789873147  
Fax    
Email  deebika06@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Alexander Mannu 
Designation  Professor Department of Pediatrics chettinad hospital and research institute 
Affiliation  chettinad hospital and research institute 
Address  Department of Pediatrics

Chennai
TAMIL NADU
603103
India 
Phone  9551607900  
Fax    
Email  paedsalex@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Alexander Mannu 
Designation  Professor Department of Pediatrics chettinad hospital and research institute 
Affiliation  chettinad hospital and research institute 
Address  Department of Pediatrics

Chennai
TAMIL NADU
603103
India 
Phone  9551607900  
Fax    
Email  paedsalex@gmail.com  
 
Source of Monetary or Material Support  
chettinad hospital and research institute kelambakam chennai 603103 
 
Primary Sponsor  
Name  Dr Deebika M 
Address  chettinad hospital and research institute kelambakkam chennai 603103 
Type of Sponsor  Other [self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Deebika M  chettinad hospital and research institute  department of pediatrics
Chennai
TAMIL NADU 
09789873147

deebika06@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Human Ethics Committee for student Research   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: T801||Vascular complications following infusion, transfusion and therapeutic injection,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Topical Heparin Gel  Heparin Gel, which has a slower transdermal penetration Group B: Heparin Gel (200 IU/g). Applied every 8 h for 72 h with aseptic precautions 
Intervention  Topical Heparin Gel  Heparin Gel, which has a slower transdermal penetration Group B: Heparin Gel (200 IU/g). Applied every 8 h for 72 h with aseptic precautions 
Intervention  Topical heparin QPS  Heparin Quick Penetrating Solution (QPS) provides faster and deeper transdermal absorption than conventional gel Group A Heparin QPS (1000 IU/mL). Applied every 8 h for 72 h with aseptic precautions 
Comparator Agent  Topical heparin QPS  Heparin Quick Penetrating Solution (QPS) provides faster and deeper transdermal absorption than conventional gel Group A Heparin QPS (1000 IU/mL). Applied every 8 h for 72 h with aseptic precautions 
 
Inclusion Criteria  
Age From  1.00 Year(s)
Age To  12.00 Year(s)
Gender  Both 
Details  Age 1 to 12 years
Those who require more than 48 h IV therapy
 
 
ExclusionCriteria 
Details  Heparin hypersensitivity, bleeding disorders, anticoagulant therapy, local infection, or critical illness requiring central lines.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Incidence of superficial thrombophlebitis assessed daily for 5 days or until
cannula removal using the Visual Infusion Phlebitis (VIP) Score.
 
It is assessed daily for 5 days or until
cannula removal using the Visual Infusion Phlebitis (VIP) Score.
 
 
Secondary Outcome  
Outcome  TimePoints 
Secondary Outcomes is Time to
onset of thrombophlebitis. Severity (graded by VIP score). Local adverse events (erythema,
rash.). Expected Outcomes The study is expected to determine whether Heparin QPS solution
provides superior protection against superficial thrombophlebitis compared to Heparin gel in
pediatric patients.  
It is assessed daily for 5 days or until
cannula removal using the Visual Infusion Phlebitis (VIP) Score.
 
 
Target Sample Size   Total Sample Size="120"
Sample Size from India="120" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   23/12/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial
Modification(s)  
Years="0"
Months="1"
Days="5" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Introduction
Peripheral intravenous cannulation is one of the most frequently performed procedures in hospitalized children. Despite its necessity it is often complicated by superficial thrombophlebitis leading to pain, premature catheter removal, interruption of therapy, and increased morbidity. The incidence of thrombophlebitis in pediatric populations varies between 25 to 60 percent depending on cannula size, site, dwell time, and preventive measures used. Topical heparin preparations have been studied for their role in reducing local inflammation and thrombosis. Two formulations commonly used are Heparin Quick Penetrating Solution QPS which offers enhanced absorption through the skin and Heparin Gel which has a slower transdermal penetration. While both have shown efficacy in adults, comparative studies in children are scarce. This study aims to prospectively compare the efficacy of Heparin QPS solution and Heparin gel in preventing superficial thrombophlebitis in children undergoing peripheral intravenous therapy.

Study Objectives
Primary Objective To compare the efficacy of Heparin QPS solution versus Heparin gel in preventing superficial thrombophlebitis in children.
Secondary Objectives To assess the time to onset of thrombophlebitis if any in both groups. To compare the severity of thrombophlebitis using a standardized scoring system. To evaluate local adverse effects of both preparations.

Study Design
Study Design Prospective randomized open label parallel group study.
Study Setting In patient department of Pediatrics Chettinad Hospital and Research Institute Kelambakkam Chennai 603103.
Study Population Children aged 1 to 12 years requiring intravenous cannulation for more than 48 hours.

Number of Subjects or Sample Size
Sample Size Based on prior studies showing an incidence difference of 20 percent in thrombophlebitis with topical heparin power 80 percent alpha 0.05 the estimated sample size is 60 patients per group total 120.

Study Methodology or Procedure
Study Design Prospective randomized open label parallel group study.
Study Setting In patient department of Pediatrics Chettinad Hospital and Research Institute Kelambakkam Chennai 603103.
Study Population Children aged 1 to 12 years requiring intravenous cannulation for more than 48 hours.
Sample Size Based on prior studies showing an incidence difference of 20 percent in thrombophlebitis with topical heparin power 80 percent alpha 0.05 the estimated sample size is 60 patients per group total 120.

Inclusion Criteria
1. Children aged 1 to 12 years.
2. Hospitalized and requiring IV cannulation for at least 48 hours.
3. Written informed consent from parents or guardians.

Exclusion Criteria
1. Known hypersensitivity to heparin or excipients.
2. Bleeding disorders or anticoagulant therapy.
3. Severe skin disease or infection at the cannulation site.
4. Critically ill children in shock requiring central lines.

Randomization
Participants will be randomized into two groups using a computer generated random sequence
Group A Heparin QPS solution applied topically around the cannula site every 8 hours for 72 hours or until discharge.
Group B Heparin gel applied similarly every 8 hours for 72 hours or until discharge.

Blinding
Open label as blinding is not feasible due to different formulations.

Study Intervention
Application of allocated formulation around the cannula insertion site using aseptic precautions.

Study Outcome or End Points
Primary Outcome Incidence of superficial thrombophlebitis assessed daily for 5 days or until cannula removal using the Visual Infusion Phlebitis VIP Score.
Secondary Outcomes Time to onset of thrombophlebitis. Severity graded by VIP score. Local adverse events such as erythema and rash.

Expected Outcomes
The study is expected to determine whether Heparin QPS solution provides superior protection against superficial thrombophlebitis compared to Heparin gel in pediatric patients. Results may guide standard protocols for thrombophlebitis prevention in children potentially reducing morbidity and healthcare costs.

Ethical Considerations
This study will be conducted after getting approval from my Ethics Committee and after getting registered to the Clinical Trial Registry of India. Informed consent from parents or guardians. Assent from children where appropriate. Both preparations are already in clinical use hence minimal risk. Confidentiality of patient data will be maintained.

Study Duration
Three months.

References
1. Rabbani Tappa et al Comparison of the efficacy of topical heparin quick penetrating solution and intravenous hydrocortisone in the prevention of thrombophlebitis A randomized controlled study Journal of Clinical and Scientific Research 14 1 pages 45 to 49 Jan to Mar 2025 DOI 10.4103 jcsr jcsr 223 23
2. Chauhan A P Jain M Mehta J Shah A Thomas S M 2024 A prospective randomized comparative study to evaluate the safety and efficacy of topical quick penetrating solution QPS of Heparin 1000 IU per ml versus Heparin gel 200 IU per ml in prevention of intravenous cannula related thrombophlebitis in post operative onco surgical intensive care unit ICU patients Indian Journal of Clinical Anaesthesia 11 4 448 to 452 https doi.org 10.18231 j.ijca.2024.084
3. Bajpai V Patel T K Dwivedi P et al Efficacy and safety of quick penetrating solution heparin quick penetrating solution diclofenac and heparin gel in the prevention of infusion associated superficial thrombophlebitis A randomized controlled trial Perspectives in Clinical Research 2024 15 4 195 to 201 doi 10.4103 picr.picr 305 23
4. Dahal A S Tuitui R Shrestha P D Sharma B Acharya S and Dahal P 2020 Effectiveness of Glycerin Magnesium Sulphate Versus Heparin Benzyl Nicotinate Application Among Children with Phlebitis Journal of Nepal Paediatric Society 40 1 21 to 27
 
Close